Real-world data shows Leqembi stabilizes early-stage Alzheimer's

Nearly 83% of patients with early-stage Alzheimer's disease maintained or improved their cognitive status after an average of 17 months on Leqembi, according to the retrospective LEADER study presented at the Alzheimer's Association International Conference in London. These findings reflect consistent outcomes across diverse patient demographics and clinical settings.

Today, 18:52· Corp and Tech· 1,651 reads

The LEADER study evaluated 432 patients across 13 clinical sites in the United States, tracking treatment outcomes through electronic medical records and clinician assessments. Data revealed that 75.9% of participants remained stable, while 6.6% experienced a measurable improvement in their condition. These results were uniform regardless of a patient's sex, race, ethnicity, or APOE genotype.

Safety profiles remained consistent with the FDA-approved label for the drug. Amyloid-related imaging abnormalities, or ARIA, occurred in 12.3% of the study population, with most cases presenting as asymptomatic or mild. Notably, the incidence of these abnormalities did not increase significantly among patients concurrently using antithrombotic medications. Nearly 87% of the cohort opted to continue their Leqembi regimen, underscoring the long-term persistence observed in real-world practice.

Real-world data shows Leqembi stabilizes early-stage Alzheimer's

Comments (0)